Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that the f...
Spinal cord injury (SCI) is a sudden disruption of the spinal cord's neural tissue within the spinal canal, caused by trauma, disease, or degeneration. Thi...
The U.S. Food and Drug Administration (FDA) approved Merilog (insulin aspart szij) as a Novolog biosimilar to (insulin aspart) to improve glycemi...
Ultragenyx Pharmaceutical Inc. announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the Biologics License Applicatio...
Grifols , a global healthcare company and leading manufacturer of plasma-derived medicines, announced it has finished recruiting the second cohort of...
Biogen Inc. and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) t...
Merck known as MSD outside of the United States and Canada, announced that the European Commission (EC) has conditionally approved WELIREG® ...
3Z Pharmaceuticals announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positio...
AltaPointe Health, a leading provider of behavioral health services in Alabama, is making strides in addressing substance use disorders among wo...
Rznomics announced on the 14th that its anticancer drug, RZ-001, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for t...
Aveva Drug Delivery systems (A DifGen company), a leader in transdermal drug delivery systems based out of Miramar - Florida is proud t...
Exelixis, Inc. announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with...
Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) ...
© 2025 Biopharma Boardroom. All Rights Reserved.
